Breaking News Instant updates and real-time market news.

IOVA

Iovance Biotherapeutics

$17.83

0.7 (4.09%)

07:09
05/31/19
05/31
07:09
05/31/19
07:09

Iovance Biotherapeutics announces updated data from LN-145 study

Iovance Biotherapeutics announced updated data from studies of TIL therapy LN-145 in patients with advanced cervical cancer and TIL therapy lifileucel in advanced melanoma. At 7.4-month median follow-up in the ongoing study of LN-145 in advanced cervical cancer, an 11% complete response rate, or CR, was seen. Furthermore, the median duration of response had not been reached. At 8.8-month median follow-up in the ongoing study of lifileucel in advanced melanoma, median duration of response had not been reached. Updated data from the ongoing innovaTIL-04 and innovaTIL-01 studies will be presented at the American Society of Clinical Oncology, or ASCO. As of May 14, data from the innovaTIL-04 study in 27 patients with recurrent, metastatic or persistent cervical cancer demonstrated an objective response rate of 44% and a disease control rate of 85%. At 7.4-month median follow-up, 10 patients maintained a response and the median DOR had not been reached. The mean patient age was 45 years and study participants had experienced a mean of 2.4 prior lines of therapy. As of May 8, results from Cohort 2 in the ongoing innovaTIL-01 study demonstrated an ORR of 38% in 66 consecutively dosed post-PD-1 patients with Stage IIIC/IV unresectable melanoma. In this study, patients had experienced a mean of 3.3 lines of prior therapy including anti-PD1 blocking antibody, and the patients had a high baseline tumor burden. The disease control rate was 80%. At 8.8-month median follow-up, median DOR had not been reached.

  • 31

    May

  • 04

    Jun

  • 10

    Jun

  • 19

    Jun

  • 26

    Jun

IOVA Iovance Biotherapeutics
$17.83

0.7 (4.09%)

05/23/19
WELS
05/23/19
NO CHANGE
Target $32
WELS
Outperform
Iovance Biotherapeutics price target raised to $32 from $23 at Wells Fargo
Wells Fargo analyst Jim Birchenough raised his price target for Iovance Biotherapeutics to $32 from $23 following FDA breakthrough therapy designation for its TIL cell therapy LN-145 in cervical cancer. With ongoing pivotal development in melanoma, the analyst sees a second potential accelerated path to market with breakthrough therapy designation in cervical cancer and sees upside potential to further regulatory update on LN145. Birchenough reiterates an Outperform rating on the shares.
05/16/19
BARD
05/16/19
NO CHANGE
Target $34
BARD
Outperform
Iovance Biotherapeutics price target raised to $34 from $29 at Baird
Baird analyst Madhu Kumar raised his price target for Iovance Biotherapeutics to $34 from $29 and maintained an Outperform rating, citing increased tumor-infiltrading lymphocyte technology conviction on ASCO abstracts in cervical cancer and metastatic melanoma. The abstracts for Phase 2 data for TIL technology increases his conviction in Iova's TILs, particularly in cervical cancer, the analyst says in a research note.
05/16/19
JEFF
05/16/19
NO CHANGE
Target $29
JEFF
Buy
Jefferies calls Iovance 'big winner' at ASCO, sees up to 40% share rally
Jefferies analyst Biren Amin calls the data reported by Iovance Biotherapeutics (IOVA) the "big winner" for the American Society of Clinical Oncology annual meeting. The ASCO update suggests Iovance's tumor infiltrating lymphocytes therapy could open the door for cell therapy in the "lucrative" solid-tumor market, Amin tells investors in a research note. He points out the company reported that no new patients have progressed in the melanoma trial and offered first evidence of clinically meaningful durability for TIL therapy. Also, its cervical data that reported a 44% overall response rate is three-times greater than reported with Merck's (MRK) Keytruda in a similar patient population, contends Amin. He believes last night's update could drive a 30%-40% rally in shares of Iovance. The analyst keeps a Buy rating on the name with a $29 price target. Iovance in premarket trading is up 26%, or $2.97, to $14.20.
05/07/19
PIPR
05/07/19
NO CHANGE
Target $20
PIPR
Overweight
Iovance Biotherapeutics well positioned in T-cell therapy, says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro kept his Overweight rating and $20 price target on Iovance Biotherapeutics after its Q1 results also disclosed that 3 of its abstracts submitted to ASCO have been accepted. The analyst believes that the company's lifileucel in melanoma update has a "clear opportunity to improve", whiles its LN-145 in cervical cancer data set could be supportive of an accelerated development path. Catanzaro sees Iovance Biotherapeutics as a "best-positioned T-cell therapy" stock, with $440M in cash on hand being sufficient to fund its operations into 2022.

TODAY'S FREE FLY STORIES

KRYS

Krystal Biotech

$37.20

7.92 (27.05%)

11:46
06/24/19
06/24
11:46
06/24/19
11:46
Recommendations
Krystal Biotech analyst commentary  »

Krystal Biotech price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

TLRD

Tailored Brands

$6.11

0.565 (10.20%)

11:45
06/24/19
06/24
11:45
06/24/19
11:45
Options
Tailored Brands call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPOT

Spotify

$149.94

1.77 (1.19%)

, AAPL

Apple

$199.39

0.62 (0.31%)

11:44
06/24/19
06/24
11:44
06/24/19
11:44
Periodicals
Apple hits back at Spotify's claims of unfair App Store treatment, AI reports »

Apple (AAPL) is hitting…

SPOT

Spotify

$149.94

1.77 (1.19%)

AAPL

Apple

$199.39

0.62 (0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

11:43
06/24/19
06/24
11:43
06/24/19
11:43
General news
6-Month Bill Auction Total Amount data reported »

6-Month Bill Auction…

11:43
06/24/19
06/24
11:43
06/24/19
11:43
General news
3-Month Bill Auction Total Amount data reported »

3-Month Bill Auction…

OXFD

Oxford Immunotec

$13.88

-0.22 (-1.56%)

11:37
06/24/19
06/24
11:37
06/24/19
11:37
Hot Stocks
Oxford Immunotec appoints Patrick Balthrop, Sr. as Chairman »

Oxford Immunotec…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPOT

Spotify

$149.99

1.82 (1.23%)

, DE

Deere

$167.23

2.94 (1.79%)

11:33
06/24/19
06/24
11:33
06/24/19
11:33
On The Fly
Spotify downgrade, Deere upgrade among today's top analyst calls »

Check out today's top…

SPOT

Spotify

$149.99

1.82 (1.23%)

DE

Deere

$167.23

2.94 (1.79%)

AGCO

Agco

$76.63

1.92 (2.57%)

IP

International Paper

$42.49

-1.13 (-2.59%)

OXY

Occidental Petroleum

$49.84

-0.78 (-1.54%)

APC

Anadarko

$70.20

-0.17 (-0.24%)

OAS

Oasis Petroleum

$5.45

-0.27 (-4.72%)

SHOP

Shopify

$315.91

-10.77 (-3.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 24

    Jun

  • 25

    Jun

  • 26

    Jun

  • 10

    Jul

  • 17

    Jul

  • 27

    Aug

  • 04

    Sep

  • 05

    Sep

  • 05

    Sep

FB

Facebook

$193.42

2.26 (1.18%)

11:30
06/24/19
06/24
11:30
06/24/19
11:30
Options
Lots of likes for short-term Facebook upside calls »

Lots of likes for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 16

    Jul

SIG

Signet Jewelers

$17.49

-0.13 (-0.74%)

11:25
06/24/19
06/24
11:25
06/24/19
11:25
Options
Signet Jewelers call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TVTY

Tivity Health

$17.18

-0.23 (-1.32%)

11:24
06/24/19
06/24
11:24
06/24/19
11:24
Conference/Events
Tivity Health management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 14

    Aug

  • 15

    Aug

11:20
06/24/19
06/24
11:20
06/24/19
11:20
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
06/24/19
06/24
11:17
06/24/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
06/24/19
06/24
11:16
06/24/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UPS

UPS

$100.87

-1.29 (-1.26%)

11:15
06/24/19
06/24
11:15
06/24/19
11:15
Options
UPS put volume heavy and directionally bearish »

Bearish flow noted in UPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 26

    Jun

  • 24

    Jul

11:15
06/24/19
06/24
11:15
06/24/19
11:15
General news
Breaking General news story  »

6-Month Bill Auction to…

11:15
06/24/19
06/24
11:15
06/24/19
11:15
General news
Breaking General news story  »

3-Month Bill Auction to…

SRPT

Sarepta

$127.90

-2.01 (-1.55%)

, PFE

Pfizer

$43.59

-0.09 (-0.21%)

11:11
06/24/19
06/24
11:11
06/24/19
11:11
On The Fly
Before the Move: Watch Sarepta ahead of Pfizer's DMD gene therapy data »

Ahead of the Parent…

SRPT

Sarepta

$127.90

-2.01 (-1.55%)

PFE

Pfizer

$43.59

-0.09 (-0.21%)

SLDB

Solid Biosciences

$4.91

-0.07 (-1.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 19

    Aug

  • 28

    Aug

  • 16

    Sep

GLW

Corning

$33.15

-0.1 (-0.30%)

11:08
06/24/19
06/24
11:08
06/24/19
11:08
Recommendations
Corning analyst commentary at JPMorgan »

Drop in LCD TV panel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSN

Tyson Foods

$81.18

1.87 (2.36%)

11:05
06/24/19
06/24
11:05
06/24/19
11:05
Options
Tyson Foods call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$45.86

-3.5 (-7.09%)

, CELG

Celgene

$94.16

-4.76 (-4.81%)

10:59
06/24/19
06/24
10:59
06/24/19
10:59
Periodicals
Bristol-Myers' merger headaches could be 'contagious,' STAT News says »

Bristol-Myers Squibb…

BMY

Bristol-Myers

$45.86

-3.5 (-7.09%)

CELG

Celgene

$94.16

-4.76 (-4.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 25

    Jul

  • 03

    Sep

  • 16

    Sep

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

LN

Line Corp.

$28.08

-0.17 (-0.60%)

10:54
06/24/19
06/24
10:54
06/24/19
10:54
Upgrade
Line Corp. rating change  »

Line Corp. now fairly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FXI

iShares China Large-Cap ETF

$42.65

0.15 (0.35%)

10:50
06/24/19
06/24
10:50
06/24/19
10:50
Options
Heavy call volume in China Largecap ETF adjusts existing position »

Heavy call volume in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAVM

PAVmed

$1.24

0.015 (1.22%)

10:49
06/24/19
06/24
10:49
06/24/19
10:49
Hot Stocks
PAVmed announces FDA 510(k) clearance for EsoCheck »

PAVmed announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

LN

Line Corp.

$28.08

-0.17 (-0.60%)

10:46
06/24/19
06/24
10:46
06/24/19
10:46
Upgrade
Line Corp. rating change at Goldman Sachs »

Line Corp. upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBX

Dropbox

$25.29

0.3 (1.20%)

10:45
06/24/19
06/24
10:45
06/24/19
10:45
Options
Dropbox call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.